10 Liquid Biopsy Companies in the Money
10 privately-held diagnostics developers primarily focused on liquid biopsy tests, ranked by total money raised from venture capital firms.
UnitedHealthcare To Cover Genetic Testing for Precision Medicine in Depression, Anxiety
The nation’s largest private health insurer, UnitedHealthcare, announced August 1 that it will cover testing that will allow physicians to match their patients to...
Mining the Microbiome: Microbiome startups are proliferating, exploring new markets, and colonizing diverse therapeutic...
It would be hard to find an area of health where the microbiome has not been implicated as a major player. The microbiome is...
Top 10 Sequencing Companies
Five years after the introduction of the $1,000 genome, the sequencing field remains rife with chatter about pushing the cost much lower—not only to $100...
10x Genomics Graduates from ‘Super Success’ to $100M IPO
10x Genomics has disclosed plans to raise $100 million through an initial public offering, according to a registration statement filed with the U.S. Securities...
Invitae Offers Free Genetic Testing for Four Conditions
Invitae said it is offering for free its Detect genetic testing programs for four conditions: Muscular dystrophy, hereditary prostate cancer, familial cardiomyopathy and arrhythmia,...
EMBL-EBI Launches Free Genetic Disease Diagnostic Software
Researchers at the University of Edinburgh and the European Bioinformatics Institute at the European Molecular Biology Laboratory (EMBL-EBI) have introduced a new diagnostic genome-wide...
Coffee Improves Gut Motility by Altering Gut Microbiota
Data presented yesterday at the Digestive Disease Week (DDW) 2019 Conference by researchers from University of Texas, Galveston, suggest that the effects of coffee...
Clinical Urologists Group Supports Genomic Testing for Prostate Cancer
AACU statement encourages use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients
![A liquid biopsy test has detected changes in the BRCA1 or BRCA2 genes associated with ovarian and breast cancer that signal when the disease stops responding to treatment through platinum chemotherapy or poly ADP-ribose polymerase (PARP) inhibitors. [Source: © freshidea/Fotolia]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1322-218x150.jpeg "Ovarian Cancer Blood Test May Eliminate Need for Diagnostic Exploratory Surgery")
Ovarian Cancer Blood Test May Eliminate Need for Diagnostic Exploratory Surgery
Scientists at Uppsala University and the Sahlgrenska Academy, University of Gothenburg say they have developed a blood test that may provide a more precise...
